Unexpected low efficacy of stealth liposomal doxorubicin (Caelyx) and vinorelbine in metastatic breast cancer

Lorenza Rimassa, Carlo Carnaghi, Isabella Garassino, Piermario Salvini, Valeria Ginanni, Giuseppe Gullo, Emanuela Morenghi, Armando Santoro

Research output: Contribution to journalArticlepeer-review

Abstract

In this phase II study, 23 patients with metastatic breast cancer were treated with a combination of Caelyx (40 mg/m 2 on day 1) and vinorelbine (20 mg/m 2 on days 1 and 8) every 4 weeks. According to the statistical design, enrollment was closed after the first stage due to the low response rate observed (four partial remissions, 12 stabilizations). Toxicity was acceptable, however, grade 3-4 neutropenia was not negligible. Our study does not support the development of this combination in advanced breast cancer.

Original languageEnglish
Pages (from-to)185-188
Number of pages4
JournalBreast Cancer Research and Treatment
Volume77
Issue number2
DOIs
Publication statusPublished - Jan 2003

Keywords

  • Advanced breast cancer
  • Caelyx
  • Doxorubicin
  • Pegylated liposomal
  • Vinorelbine

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Unexpected low efficacy of stealth liposomal doxorubicin (Caelyx) and vinorelbine in metastatic breast cancer'. Together they form a unique fingerprint.

Cite this